The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX
3
CR1 or fractalkine antagonist.
Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
申请人:Drexel University College of Medicine Philadelphia Health & Education Corporation d/b/a
公开号:US20130156761A1
公开(公告)日:2013-06-20
The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX
3
CR1 or fractalkine antagonist.
Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs
申请人:Frank Robert
公开号:US20090215758A1
公开(公告)日:2009-08-27
The invention relates to 2,5-disubstituted thiazol-4-one derivatives and to their use in the production of drugs, to methods for producing them and to drugs containing said compounds.
Compounds useful for inhibiting metastasis from cancer and methods using same
申请人:Drexel University
公开号:US10414771B2
公开(公告)日:2019-09-17
The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.